imbiologics Venture Capital
4 known investors
The page is a stock price information page (share price, trading volume, and market cap history) rather than a descriptive company page, so it provides no usable detail about what the company does.
Also known as ImBiologics Β· IMBiologics Corp. Β· μμ΄μ λ°μ΄μ€ Β· μμ΄μ λ°μ΄μ€λ‘μ§μ€
Investors Β· 4
Company profile
researched Aug 2026ImBiologics (μμ΄μ λ°μ΄μ€λ‘μ§μ€) is a South Korea-based biotechnology company specializing in the discovery and development of innovative antibody therapeutics. Established in August 2020, the company builds its pipeline around immunomodulatory biologics, targeting autoimmune diseases and immuno-oncology indications where it states existing therapies leave unmet medical need.
The company's work centers on an in-house antibody modality design and optimization platform, referred to as IM-OpDECon, which it uses to construct and optimize antibody formats across antigen binding, antibody function and biophysical properties. Named programs referenced on the company's site include IMB-101 and IMB-106. The company describes an ambition to grow into a biotech capable of independently developing and obtaining approval for novel drugs, positioning itself in immune-mediated disease.
Business model
The company develops antibody drug candidates in-house and pursues partnering and licensing-out of programs with global partners, alongside investor relations activity indicating external capital raising.
Traction
Company communications reference clinical attention for IMB-101, preclinical-stage progress and licensing-out expectations for IMB-106, and expectations that clinical results in 2027 would be a value inflection point.
Latest developments
In mid-2026, company press coverage highlighted a global strategy centered on IMB-106 with expectations spanning preclinical work through licensing-out, business development discussions for next-generation pipeline assets at BIO USA, attention on the IMB-101 clinical program and follow-on licensing prospects, and commentary that 2027 clinical results would be a catalyst for the company's valuation.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
The company positions its differentiation in the ability to design and optimize varied antibody modalities via IM-OpDECon in order to address indications in autoimmune disease and immuno-oncology that it says are not resolved by existing therapies.
Technology
ImBiologics' core technology is IM-OpDECon, described as an optimal antibody modality construction technology. It is applied to expand the pipeline by optimizing antigen binding, antibody function and antibody developability/physical properties, and supports the use of multiple antibody modalities.
Go-to-market
The company pursues business development with global partners, including out-licensing discussions and participation in industry conferences such as BIO USA, where it discussed commercialization of next-generation pipeline assets.
Geography
Headquartered in South Korea, with business development activity aimed at global partners and participation in international industry events.
History
ImBiologics was founded in August 2020 as a company dedicated to developing innovative antibody drugs, operating under the slogan "Innovative Medicines based on ImmunoModulatory Biologics."
Compiled by commissioned research from 2 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 4
launches, deals, and filingsPress release referenced on the company's site describing a global push centered on the IMB-106 program with expectations spanning preclinical development and licensing-out.
The company reported beginning commercialization discussions for its next-generation pipeline at the BIO USA convention.
Press item noting focus on the IMB-101 clinical program, with follow-on licensing-out cited as a key variable.
Press item stating that clinical results expected in 2027 would be a momentum driver for the company's value.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 2
primary sources listed
- imbiologics Venture Capitalimbiologics.com Β· web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does imbiologics Venture Capital do?
- Korean biotech developing immunomodulatory antibody therapeutics for autoimmune disease and immuno-oncology.
- Who are imbiologics Venture Capital's investors?
- imbiologics Venture Capital's investors include Aju IB Invesment Corporation, Atinum Investment Co. Ltd., IMM Investment Japan, Solidus Investment.